Cobra Biologics Ltd. Re-Launched With New Company Branding to Give a Fresh Corporate Identity to Seal Plans for Future Growth

October 03, 2011 -- Following the acquisition by Cobra Biologics Holding AB of Recipharm AB’s biologics business on 30th June 2011, we are pleased to announce that from 3rd October 2011, the business will be re-launched and re-branded under the name of Cobra Biologics.

Cobra Biologics’ senior management have significant experience in biopharmaceutical drug development gained from working in pharmaceutical and biotechnology companies. The team at Cobra Biologics are proud of our:

Expertise: Cobra Biologics is a Contract Manufacturing Organization supporting the global life sciences industry in the development and manufacture of monoclonal antibodies, recombinant proteins, DNA, viruses and cell line derived products.

Experience: Over 13 years of track record in producing biopharmaceuticals has given Cobra Biologics’ people a unique knowledge base as both manufacturer and service providers for the life sciences market.

Excellence: Every program complies with cGMP standards and is conceived with an unmatched quality derived from the know-how of its highly qualified, flexible and dedicated people.

Cobra Biologics has two GMP approved facilities; Södertälje in Sweden, located 30km south of Stockholm in the centre of the major Scandinavian biomanufacuturing hub and Keele in the centre of the UK, 40km south of Manchester.

Julian Hanak, Commercial Director, Cobra Biologics commented: “From both sites, our organisation offers a broad range of integrated and stand-alone development services, stretching from cell line development through to the supply of investigational medicinal product, including regulatory support. We take pride in manufacturing excellence, delivering what we promise and helping our customers to develop drugs for the benefit of patients.”

Peter Coleman, CEO, Cobra Biologics said: “As a newly independent organisation, we are delighted to be rebranding with a name that resonates very strongly with the biopharmaceutical sector and which plays to our long established heritage and recognised expertise.”

He continued, “Indeed, our commitment to providing the best services through employing highly skilled, experienced staff has proved a critical success factor as we continue to expand and grow our business in the biopharmaceuticals contract manufacturing market.”

For more information about Cobra Biologics, please contact Peter Coleman, CEO, on 01782 714181 or email peter.coleman@cobrabio.com .

For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0) 207 861 3019 or email: t.jervis@defacto.com